Drug Trial Radar · NCT05952206
Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy
Last checked: Nov 19, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
2,312
Actual
Start
Oct 13, 2023
Primary completion
Jan 13, 2027
Study completion Jan 13, 2030
Sponsor
- Lead sponsor
- iVascular S.L.U.Industry
- Sponsor type
- Industry
- First posted
- Jul 19, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 95 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Factorial 2x2, all-comer, multicentre, randomized controlled trial (ratio 1:1:1:1). First, the study will compare (first randomization) the non-inferiority in target lesion failure of angiolite stent versus Xience stent family. Immediately after the first randomization, the study compares (second randomization) the superiority in bleeding Bleeding Academic Research Consortium (BARC) 2, 3, or 5 of abbreviated DAPT versus standard of care. Both primary endpoints will be evaluated at 12 months of follow-up. The study will be open-label for the stent type and the antiplatelet regimen.
Conditions
- Coronary Artery Disease
Interventions
Angiolite: Sirolimus-eluting stentDevice
The angiolite stent (iVascular, Barcelona, Spain) is a thin-strut cobalt-chromium sirolimus-eluting stent with an open-cell design containing a durable biostable coating composed of three layers - acrylate to ensure adhesion to the metal surface, fluoroacrylate that carries the sirolimus, and a top layer of fluoroacrylate to control drug release.
Xience: Everolimus-eluting stentDevice
The Xience stent family (Abbott vascular, California, United States of America), characterized by an L-605 cobalt-chromium (CoCr) is a thin-strut cobalt-chromium everolimus-eluting stent with an open-cell design containing a nonerodable polymer made of PBMA, a reservoir made of a fluorinated copolymer of vinylidene fluoride and hexafluoropropylene monomers. Xience™ stent family includes XIENCE Skypoint™ and XIENCE Sierra™
1-month DAPTDrug
DAPT with acetylsalicylic acid + prasugrel or ticagrelor for 1 month. Then, only the same oral P2Y12 inhibitor (clopidogrel, prasugrel, and ticagrelor) up to 12 months. The type of agent and treatment duration will be selected according to the clinical characteristic of the patient: Acute coronary syndrome or Chronic coronary syndrome and Need for OAC or No need for OAC
12-month DAPT (Standard of care)Drug
DAPT with acetylsalicylic acid and prasugrel or ticagrelor up to 12 months. The type of agent and treatment duration will be selected according to the clinical characteristic of the patient: Acute coronary syndrome or Chronic coronary syndrome and Need for OAC or No need for OAC
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine the rate of target lesion failure between angiolite stent and Xience stent family (tested for non-inferiority) in both the standard of care DAPT regimen and abbreviated antiplatelet therapy group.Time frame: 1 year
- To determine the rate of clinically relevant bleeding events (BARC 2, 3, or 5) between an abbreviated DAPT regimen and the standard of care DAPT (tested for superiority of the experimental arm).Time frame: 1 year
Locations
38 sites in 3 countries. Site status is shown where the registry gives one.
IMELDA
Bonheiden, Belgium
CHU Marie Curie
Charleroi, Belgium
ZOL GENK
Genk, Belgium
CHC Montlégia
Liège, Belgium
Hospital de La Citadelle
Liège, Belgium
Chu Ambroise Pare
Mons, Belgium
Az Delta
Roeselare, Belgium
Az Turnhout
Turnhout, Belgium
Chu Lille
Lille, France
Icps Massy
Massy, France
Ipcs Quincy
Quincy-sous-Sénart, France
Chu Toulouse
Toulouse, France
Complejo Hospitalario Universitario A Coruña
A Coruña, Spain
Complejo Hospitalario Torrecárdenas
Almería, Spain
Hospital Clínic de Barcelona
Barcelona, Spain
Hospital de La Santa Creu I Sant Pau
Barcelona, Spain
Hospital Germans Trias I Pujol
Barcelona, Spain
Hospital Universitario de Bellvitge
Barcelona, Spain
Hospital Universitario Vall D'Hebrón
Barcelona, Spain
Hospital San Pedro de Alcantara
Cáceres, Spain
Hospital Universitario Juan Ramón Jiménez
Huelva, Spain
Hospital Universitario Jerez de La Frontera
Jerez de la Frontera, Spain
Hospital Universitario de Gran Canaria Doctor Negrín
Las Palmas de Gran Canaria, Spain
Hospital Universitario de León
León, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Universitario Puerta de Hierro
Madrid, Spain
Hospital Universitario Regional de Málaga
Málaga, Spain
Hospital Universitario Virgen de La Victoria
Málaga, Spain
Hospital Clínico Universitario Virgen de La Arrixaca
Murcia, Spain
Hospital Universitari Son Espases
Palma de Mallorca, Spain
Hospital de Navarra
Pamplona, Spain
Hospital Universitario Marqués de Valdecilla
Santander, Spain
Hospital Clínico Universitario de Santiago
Santiago de Compostela, Spain
Hospital Clínico Universitario de Valencia
Valencia, Spain
Hospital Universitario Y Politécnico La Fe
Valencia, Spain
Hospital Clínico Universitario de Valladolid
Valladolid, Spain
Hospital Álvaro Cunqueiro
Vigo, Spain
Hospital Universitario Miguel Servet
Zaragoza, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.